July 1, 2004
GOLD Science Committee
Abstracts Reviewed for 2004 Update Report
1. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R,
Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency
treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348(26):2618-2625.
2. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind,
placebo controlled crossover trial of sustained release morphine for the management of refractory
dyspnoea. Bmj 2003;327(7414):523-528.
3. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic
obstructive pulmonary disease. Eur Respir J 2003;21(2):347-360.
4. Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs
levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Chest 2003;123(3):772-777.
5. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, Rengo F. Do
GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J
2003;22(3):444-449.
6. Asad N, Johnson VM, Spodick DH. Acute right atrial strain: regression in normal as well as
abnormal P-wave amplitudes with treatment of obstructive pulmonary disease. Chest
2003;124(2):560-564.
7. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment
of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial.
Respir Med 2003;97(3):212-220.
8. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary
disease. Eur Respir J 2003;21(5):892-905.
9. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway
hyperresponsiveness to methacholine. Respir Med 2003;97(6):726-733.
10. Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive
pulmonary disease: meta-analysis of randomised trials. BMJ 2003;327(7416):643.
11. Behnke M, Jorres RA, Kirsten D, Magnussen H. Clinical benefits of a combined hospital and
home-based exercise programme over 18 months in patients with severe COPD. Monaldi Arch
Chest Dis 2003;59(1):44-51.
12. Bellia V, Catalano F, Scichilone N, Incalzi RA, Spatafora M, Vergani C, Rengo F. Sleep
disorders in the elderly with and without chronic airflow obstruction: the SARA study. Sleep
2003;26(3):318-323.
13. Berry MJ, Rejeski WJ, Adair NE, Ettinger WH, Jr., Zaccaro DJ, Sevick MA. A randomized,
controlled trial comparing long-term and short-term exercise in patients with chronic obstructive
pulmonary disease. J Cardiopulm Rehabil 2003;23(1):60-68.
14. Bestall JC, Paul EA, Garrod R, Garnham R, Jones RW, Wedzicha AJ. Longitudinal trends in
exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respir
Med 2003;97(2):173-180.
15. Bolliger CT, Perruchoud AP. Functional evaluation of the lung resection candidate. Eur Respir
J 1998;11(1):198-212.
16. Borg I, Rohde G, Loseke S, Bittscheidt J, Schultze-Werninghaus G, Stephan V, Bufe A.
Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in
pulmonary diseases. Eur Respir J 2003;21(6):944-951.
17. Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, Papi A, Saetta M, Fabbri
LM, Mapp CE. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir
J 2003;21(3):450-454.
18. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, Renzi P, Nault D, Borycki E,
Schwartzman K, Singh R, Collet JP. Reduction of hospital utilization in patients with chronic
obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med
2003;163(5):585-591.
19. Bourbeau J, Ernst P, Cockcoft D, Suissa S. Inhaled corticosteroids and hospitalisation due to
exacerbation of COPD. Eur Respir J 2003;22(2):286-289.
20. Boyer A, Thiery G, Lasry S, Pigne E, Salah A, de Lassence A, Dreyfuss D, Ricard JD. Longterm mechanical ventilation with hygroscopic heat and moisture exchangers used for 48 hours: a
prospective clinical, hygrometric, and bacteriologic study. Crit Care Med 2003;31(3):823-829.
21. Brand P, Beckmann H, Maas Enriquez M, Meyer T, Mullinger B, Sommerer K, Weber N,
Weuthen T, Scheuch G. Peripheral deposition of alpha1-protease inhibitor using commercial
inhalation devices. Eur Respir J 2003;22(2):263-267.
22. Broeders ME, Molema J, Vermue NA, Folgering HT. In Check Dial: accuracy for Diskus and
Turbuhaler. Int J Pharm 2003;252(1-2):275-280.
23. Broeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD
patients: reproducibility and effect of instruction. J Aerosol Med 2003;16(2):131-141.
24. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes
following treatment for six months with once daily tiotropium compared with twice daily salmeterol
in patients with COPD. Thorax 2003;58(5):399-404.
25. Bruschi C, Crotti P, Dacosto E, Fanfulla F, Daffonchio L, Novellini R. Levodropropizine does
not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory
impairment. Pulm Pharmacol Ther 2003;16(4):231-236.
26. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial
fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21(6):1012-1016.
27. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in
patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax
2003;58(8):654-658.
28. Cai B, Zhu Y, Ma Y, Xu Z, Zao Y, Wang J, Lin Y, Comer GM. Effect of supplementing a highfat, low-carbohydrate enteral formula in COPD patients. Nutrition 2003;19(3):229-232.
29. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a
randomised controlled trial. Lancet 2003;361(9356):449-456.
30. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide
on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax
2003;58(10):855-860.
31. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW. Withdrawal from treatment as an
outcome in the ISOLDE study of COPD. Chest 2003;124(4):1350-1356.
32. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy
with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J
2003;22(6):912-919.
33. Carter R, Holiday DB, Nwasuruba C, Stocks J, Grothues C, Tiep B. 6-minute walk work for
assessment of functional capacity in patients with COPD. Chest 2003;123(5):1408-1415.
34. Castaldo RS, Celli BR, Gomez F, LaVallee N, Souhrada J, Hanrahan JP. A comparison of 5day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic
obstructive pulmonary disease. Clin Ther 2003;25(2):542-557.
35. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S.
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and
formoterol + budesonide in patients with COPD. Respir Med 2003;97(5):453-457.
36. Cazzola M, Santus P, Matera MG, Carlucci P, Belloli E, Di Marco F, Centanni S. A single high
dose of formoterol is as effective as the same dose administered in a cumulative manner in
patients with acute exacerbation of COPD. Respir Med 2003;97(5):458-462.
37.
Cazzola M, Matera MG, D'Amato M, Califano C, Sanduzzi A, Vatrella A, D'Amato G.
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment
with formoterol Turbuhaler. Pulm Pharmacol Ther 2003;16(2):105-109.
38.
Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. Symptoms are an
important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month
comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med
2003;97 Suppl A:S35-43.
39.
Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and
hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest
2003;124(5):1743-1748.
40. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway
obstruction. Eur Respir J 2003;22(2):268-273.
41. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a
summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946.
42. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a
summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946.
43. Cerveri I, Accordini S, Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, Beccaria M, Marinoni A,
Viegi G, de Marco R. Chronic cough and phlegm in young adults. Eur Respir J 2003;22(3):413-417.
44. Cogo R, Ramponi A, Scivoletto G, Rippoli R. Prophylaxis for acute exacerbations of chronic
bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical
and pharmacoeconomic study. Acta Biomed Ateneo Parmense 2003;74(2):81-87.
45. Connett JE, Murray RP, Buist AS, Wise RA, Bailey WC, Lindgren PG, Owens GR. Changes in
smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol
2003;157(11):973-979.
46. Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM. A role for anabolic steroids
in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial.
Chest 2003;124(5):1733-1742.
47. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, Barnes PJ, Donnelly LE.
Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.
Thorax 2003;58(11):942-946.
48. Dahl R, Backer V, Ollgaard B, Gerken F, Kesten S. Assessment of patient performance of the
HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med
2003;97(10):1126-1133.
49. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & fluticasone 50 microg/250
microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone
and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther
2003;16(4):241-246.
50. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable
COPD. Chest 2003;124(3):844-849.
51. de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on
anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil
2003;84(8):1154-1157.
52. Debigare R, Cote CH, Hould FS, LeBlanc P, Maltais F. In vitro and in vivo contractile
properties of the vastus lateralis muscle in males with COPD. Eur Respir J 2003;21(2):273-278.
53. del Castillo D, Barrot E, Laserna E, Otero R, Cayuela A, Castillo Gomez J. [Noninvasive
positive pressure ventilation for acute respiratory failure in chronic obstructive pulmonary disease
in a general respiratory ward]. Med Clin (Barc) 2003;120(17):647-651.
54. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S.
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir
J 2003;21(1):86-94.
55. Diehl JL, Mercat A, Guerot E, Aissa F, Teboul JL, Richard C, Labrousse J. Helium/oxygen
mixture reduces the work of breathing at the end of the weaning process in patients with severe
chronic obstructive pulmonary disease. Crit Care Med 2003;31(5):1415-1420.
56. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA.
Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J
2003;22(6):931-936.
57. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in
COPD. Respir Med 2003;97(9):1014-1020.
58. Eichenhorn MS, Wise RA, Madhok TC, Gerald LB, Bailey WC, Tashkin DP, Scanlon PD. Lack
of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest
2003;124(1):57-62.
59. Faber M, Jahnz-Rozyk K, Targowski T, Mamelka B. [Comparative analysis of the effectiveness
and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. Pol
Merkuriusz Lek 2003;14(79):36-38.
60. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of
salmeterol in COPD. Chest 2003;123(6):1817-1824.
61. Ferrarotti I, Zorzetto M, Beccaria M, Gile LS, Porta R, Ambrosino N, Pignatti PF, Cerveri I,
Pozzi E, Luisetti M. Tumour necrosis factor family genes in a phenotype of COPD associated with
emphysema. Eur Respir J 2003;21(3):444-449.
62. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE.
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe
emphysema. N Engl J Med 2003;348(21):2059-2073.
63. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract
infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide
telithromycin. J Antimicrob Chemother 2003;51(4):947-955.
64. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D,
Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T,
Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Antiinflammatory effects of the
phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2003;168(8):976-982.
65. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of rehospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J
2003;21(5):795-798.
66. Godoy I, Campana AO, Geraldo RR, Padovani CR, Paiva SA. Cytokines and dietary energy
restriction in stable chronic obstructive pulmonary disease patients. Eur Respir J 2003;22(6):920925.
67. Goldstein RS, Todd TR, Guyatt G, Keshavjee S, Dolmage TE, van Rooy S, Krip B, Maltais F,
LeBlanc P, Pakhale S, Waddell TK. Influence of lung volume reduction surgery (LVRS) on health
related quality of life in patients with chronic obstructive pulmonary disease. Thorax
2003;58(5):405-410.
68. Gorecka D, Sliwinski P, Palasiewicz G, Pachocki R, Zielinski J. Effects of almitrine bismesylate
on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate
hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study. Respiration
2003;70(3):275-283.
69. Gosker HR, Kubat B, Schaart G, van der Vusse GJ, Wouters EF, Schols AM. Myopathological
features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J
2003;22(2):280-285.
70. Gosker HR, Schrauwen P, Hesselink MK, Schaart G, van der Vusse GJ, Wouters EF, Schols
AM. Uncoupling protein-3 content is decreased in peripheral skeletal muscle of patients with
COPD. Eur Respir J 2003;22(1):88-93.
71. Gosselin N, Lambert K, Poulain M, Martin A, Prefaut C, Varray A. Endurance training improves
skeletal muscle electrical activity in active COPD patients. Muscle Nerve 2003;28(6):744-753.
72. Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, Rabe KF. Does a single
dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients
with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 2003;16(2):115-120.
73. Guleria R, Singh TR, Sinha S, Padhy AK, Gupta K, Pande JN. Effect of inhalation of
salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in
some patients with chronic stable bronchial asthma. Indian J Med Res 2003;117:158-163.
74. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and
safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus
inhaler for the treatment of COPD. Chest 2003;124(3):834-843.
75. Hansell A, Hollowell J, McNiece R, Nichols T, Strachan D. Validity and interpretation of
mortality, health service and survey data on COPD and asthma in England. Eur Respir J
2003;21(2):279-286.
76. Hasani A, Pavia D, Toms N, Dilworth P, Agnew JE. Effect of aromatics on lung mucociliary
clearance in patients with chronic airways obstruction. J Altern Complement Med 2003;9(2):243249.
77. Hernandez C, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E, Vilagut G, Collvinent
B, Rodriguez-Roisin R, Roca J. Home hospitalisation of exacerbated chronic obstructive
pulmonary disease patients. Eur Respir J 2003;21(1):58-67.
78. Highcock MP, Shneerson JM, Smith IE. Increased ventilation with NiIPPV does not necessarily
improve exercise capacity in COPD. Eur Respir J 2003;22(1):100-105.
79. Hiller FC, Alderfer V, Goldman M. Long-term use of Viozan (sibenadet HCl) in patients with
chronic obstructive pulmonary disease: results of a 1-year study. Respir Med 2003;97 Suppl
A:S45-52.
80. Holten KB. How should we manage an acute exacerbation of COPD? J Fam Pract
2003;52(10):780-782.
81. Hsiao SF, Wu YT, Wu HD, Wang TG. Comparison of effectiveness of pressure threshold and
targeted resistance devices for inspiratory muscle training in patients with chronic obstructive
pulmonary disease. J Formos Med Assoc 2003;102(4):240-245.
82. Ichinose M, Sugiura H, Yamagata S, Koarai A, Tomaki M, Ogawa H, Komaki Y, Barnes PJ,
Shirato K, Hattori T. Xanthine oxidase inhibition reduces reactive nitrogen species production in
COPD airways. Eur Respir J 2003;22(3):457-461.
83. Ind PW, Laitinen L, Laursen L, Wenzel S, Wouters E, Deamer L, Nystrom P. Early clinical
investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor
agonist for the treatment of chronic obstructive pulmonary disease symptoms. Respir Med 2003;97
Suppl A:S9-21.
84. Jakeways N, McKeever T, Lewis SA, Weiss ST, Britton J. Relationship between FEV1
reduction and respiratory symptoms in the general population. Eur Respir J 2003;21(4):658-663.
85. Jolliet P, Tassaux D, Roeseler J, Burdet L, Broccard A, D'Hoore W, Borst F, Reynaert M,
Schaller MD, Chevrolet JC. Helium-oxygen versus air-oxygen noninvasive pressure support in
decompensated chronic obstructive disease: A prospective, multicenter study. Crit Care Med
2003;31(3):878-884.
86. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone
propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21(1):6873.
87. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic
obstructive pulmonary disease: an economic evaluation. Respir Med 2003;97(1):20-26.
88. Jones AY, Dean E, Chow CC. Comparison of the oxygen cost of breathing exercises and
spontaneous breathing in patients with stable chronic obstructive pulmonary disease. Phys Ther
2003;83(5):424-431.
89. Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell
activity in patients with COPD and asthma. Eur Respir J 2003;21(4):567-573.
90. Jorgensen K, Houltz E, Westfelt U, Nilsson F, Schersten H, Ricksten SE. Effects of lung
volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe
emphysema. Chest 2003;124(5):1863-1870.
91. Jorquera J, Diaz O, Lisboa C. [Effect of ipratropium bromide on lung dynamic hyperinflation in
patients with chronic obstructive lung disease]. Rev Med Chil 2003;131(6):605-612.
92. Kalinina EP, Zhuravskaia NS, Tsyvkina GI, Koziavina NV. [Correction of immune disorders
with neoselenium in patients with chronic bronchitis]. Klin Med (Mosk) 2003;81(3):43-46.
93. Kanazawa H, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor
and endostatin in emphysema. Eur Respir J 2003;22(4):609-612.
94. Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic
obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A
systematic review of the literature. Ann Intern Med 2003;138(11):861-870.
95. Khan S, Javaid A, Ghori RA, Mahmood K, Anwer N, Khan SU, Iqbal ZH, Rahman F, Ullah S,
Imran K, Akhter N, Khan MK, Siddqui SJ, Fareed A, Khan MH. Cefaclor AF vs Clarithromycin in
acute exacerbation of chronic bronchitis (B3M-PK-AJBG). J Pak Med Assoc 2003;53(8):338-345.
96. Kurup RK, Kurup PA. Hypothalamic digoxin, hemispheric chemical dominance, and chronic
bronchitis emphysema. Int J Neurosci 2003;113(9):1241-1258.
97. Laursen LC, Lindqvist A, Hepburn T, Lloyd J, Perrett J, Sanders N, Rocchiccioli K. The role of
the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic
obstructive pulmonary disease: results of a large-scale clinical investigation. Respir Med 2003;97
Suppl A:S23-33.
98. Leidy NK, Schmier JK, Jones MK, Lloyd J, Rocchiccioli K. Evaluating symptoms in chronic
obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir
Med 2003;97 Suppl A:S59-70.
99. Lewis CA, Eaton TE, Young P, Kolbe J. Short-burst oxygen immediately before and after
exercise is ineffective in nonhypoxic COPD patients. Eur Respir J 2003;22(4):584-588.
100. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation
to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease:
Cochrane systematic review and meta-analysis. Bmj 2003;326(7382):185.
101. Lubasch A, Luck S, Lode H, Mauch H, Lorenz J, Bolcskei P, Welte T. Optimizing ceftazidime
pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. J Antimicrob
Chemother 2003;51(3):659-664.
102. Mador MJ, Bozkanat E, Kufel TJ. Quadriceps fatigue after cycle exercise in patients with
COPD compared with healthy control subjects. Chest 2003;123(4):1104-1111.
103. Maestrelli P, Paska C, Saetta M, Turato G, Nowicki Y, Monti S, Formichi B, Miniati M, Fabbri
LM. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of
severe COPD patients. Eur Respir J 2003;21(6):971-976.
104. Mahler DA, Ward J, Mejia-Alfaro R. Stability of dyspnea ratings after exercise training in
patients with COPD. Med Sci Sports Exerc 2003;35(7):1083-1087.
105. Mamoto T, Fujiwara H, Toyama Y, Hirata K, Yoshikawa J, Fujimoto S. Relationship between
exercise performance and water distribution measured by new bioelectrical impedance analysis in
patients with chronic obstructive pulmonary disease. Clin Physiol Funct Imaging 2003;23(4):230235.
106. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid
modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in
patients with emphysema. Chest 2003;124(5):1724-1732.
107. McKeough ZJ, Alison JA, Bye PT. Arm positioning alters lung volumes in subjects with COPD
and healthy subjects. Aust J Physiother 2003;49(2):133-137.
108. Mentzelopoulos SD, Zakynthinos SG, Roussos C, Tzoufi MJ, Michalopoulos AS. Prone
position improves lung mechanical behavior and enhances gas exchange efficiency in
mechanically ventilated chronic obstructive pulmonary disease patients. Anesth Analg
2003;96(6):1756-1767, table of contents.
109. Monninkhof E, van der Valk P, van der Palen J, van Herwaarden C, Partridge MR, Zielhuis G.
Self-management education for patients with chronic obstructive pulmonary disease: a systematic
review. Thorax 2003;58(5):394-398.
110. Monninkhof E, van der Valk P, van der Palen J, van Herwaarden C, Zielhuis G. Effects of a
comprehensive self-management programme in patients with chronic obstructive pulmonary
disease. Eur Respir J 2003;22(5):815-820.
111. Nandi K, Smith AA, Crawford A, MacRae KD, Garrod R, Seed WA, Roberts CM. Oxygen
supplementation before or after submaximal exercise in patients with chronic obstructive
pulmonary disease. Thorax 2003;58(8):670-673.
112. Neuzil KM, O'Connor TZ, Gorse GJ, Nichol KL. Recognizing influenza in older patients with
chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis
2003;36(2):169-174.
113. Nguyen HQ, Altinger J, Carrieri-Kohlman V, Gormley JM, Stulbarg MS. Factor analysis of
laboratory and clinical measurements of dyspnea in patients with chronic obstructive pulmonary
disease. J Pain Symptom Manage 2003;25(2):118-127.
114. O'Brien JA, Ward AJ, Jones MK, McMillan C, Lordan N. Utilization of health care services by
patients with chronic obstructive pulmonary disease. Respir Med 2003;97 Suppl A:S53-58.
115. O'Donoghue FJ, Catcheside PG, Ellis EE, Grunstein RR, Pierce RJ, Rowland LS, Collins ER,
Rochford SE, McEvoy RD. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary
disease: prevalence and associated factors. Eur Respir J 2003;21(6):977-984.
116. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the effects of
salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest
2003;123(6):1810-1816.
117. Oh EG. The effects of home-based pulmonary rehabilitation in patients with chronic lung
disease. Int J Nurs Stud 2003;40(8):873-879.
118. Paredi P, Caramori G, Cramer D, Ward S, Ciaccia A, Papi A, Kharitonov SA, Barnes PJ.
Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease. Eur Respir J
2003;21(3):439-443.
119. Patel IS, Roberts NJ, Lloyd-Owen SJ, Sapsford RJ, Wedzicha JA. Airway epithelial
inflammatory responses and clinical parameters in COPD. Eur Respir J 2003;22(1):94-99.
120. Peces-Barba G, Ruiz-Cabello J, Cremillieux Y, Rodriguez I, Dupuich D, Callot V, Ortega M,
Rubio Arbo ML, Cortijo M, Gonzalez-Mangado N. Helium-3 MRI diffusion coefficient: correlation to
morphometry in a model of mild emphysema. Eur Respir J 2003;22(1):14-19.
121. Piitulainen E, Bernspang E, Bjorkman S, Berntorp E. Tailored pharmacokinetic dosing allows
self-administration and reduces the cost of IV augmentation therapy with human alpha(1)antitrypsin. Eur J Clin Pharmacol 2003;59(2):151-156.
122. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H.
Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J
2003;21(6):939-943.
123. Prescott E, Godtfredsen N, Vestbo J, Osler M. Social position and mortality from respiratory
diseases in males and females. Eur Respir J 2003;21(5):821-826.
124. Puente-Maestu L, Luisa Sanz M, Sanz P, de Ona RJ, Arnedillo A, Casaburi R. Long-term
effects of a maintenance program after supervised or self-monitored training programs in patients
with COPD. Lung 2003;181(2):67-78.
125. Puente-Maestu L, Tena T, Trascasa C, Perez-Parra J, Godoy R, Garcia MJ, Stringer WW.
Training improves muscle oxidative capacity and oxygenation recovery kinetics in patients with
chronic obstructive pulmonary disease. Eur J Appl Physiol 2003;88(6):580-587.
126. Rabinovich RA, Figueras M, Ardite E, Carbo N, Troosters T, Filella X, Barbera JA,
Fernandez-Checa JC, Argiles JM, Roca J. Increased tumour necrosis factor-alpha plasma levels
during moderate-intensity exercise in COPD patients. Eur Respir J 2003;21(5):789-794.
127. Raherison C, Poirier R, Daures JP, Romand P, Grignet JP, Arsac P, Tartavel JM, Touron D,
Taytard A. Lower respiratory tract infections in adults: non-antibiotic prescriptions by GPs. Respir
Med 2003;97(9):995-1000.
128. Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable
chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax
2003;58(7):580-584.
129. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer JP, Peel N, Haim
M, Bruyere O, Reginster JY. Inhaled corticosteroids effects on bone in asthmatic and COPD
patients: a quantitative systematic review. Osteoporos Int 2003;14(3):179-190.
130. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in
chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003;167(6):880-888.
131. Rooyackers JM, Berkeljon DA, Folgering HT. Eccentric exercise training in patients with
chronic obstructive pulmonary disease. Int J Rehabil Res 2003;26(1):47-49.
132. Rupp J, Kothe H, Mueller A, Maass M, Dalhoff K. Imbalanced secretion of IL-1beta and IL1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J
2003;22(2):274-279.
133. Saey D, Debigare R, LeBlanc P, Mador MJ, Cote CH, Jobin J, Maltais F. Contractile leg
fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2003;168(4):425-430.
134. Sans-Torres J, Domingo C, Moron A, Rue M, Marin A, Saas-Torres J. Long-term effects of
almitrine bismesylate in COPD patients with chronic hypoxaemia. Respir Med 2003;97(6):599-605.
135. Sansores R, Ramirez-Vanegas A, Reddy C, Mejia-Alfaro R. Effect of the combination of two
bronchodilators on breathlessness in patients with chronic obstructive pulmonary disease. A
crossover clinical trial. Arch Med Res 2003;34(4):292-297.
136. Santus P, Pecchiari M, Carlucci P, Boveri B, Di Marco F, Castagna F, Centanni S.
Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. Eur
Respir J 2003;21(1):82-85.
137. Schulz C, Petrig V, Wolf K, Kratzel K, Kohler M, Becker B, Pfeifer M. Upregulation of MCAM
in primary bronchial epithelial cells from patients with COPD. Eur Respir J 2003;22(3):450-456.
138. Schunemann HJ, Griffith L, Stubbing D, Goldstein R, Guyatt GH. A clinical trial to evaluate
the measurement properties of 2 direct preference instruments administered with and without
hypothetical marker states. Med Decis Making 2003;23(2):140-149.
139. Schuurmans MM, Diacon AH, Bolliger CT. Functional evaluation before lung resection. Clin
Chest Med 2002;23(1):159-172.
140. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. Six-minute walk
distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course
layout and length. Am J Respir Crit Care Med 2003;167(11):1522-1527.
141. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary
disease: does the dose matter? Eur Respir J 2003;21(2):260-266.
142. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic
obstructive pulmonary disease: scientific review. JAMA 2003;290(17):2301-2312.
143. Singh V, Khandelwal DC, Khandelwal R, Abusaria S. Pulmonary rehabilitation in patients with
chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2003;45(1):13-17.
144. Sitkauskiene B, Sakalauskas R, Malakauskas K, Lotvall J. Reversibility to a beta2-agonist in
COPD: relationship to atopy and neutrophil activation. Respir Med 2003;97(6):591-598.
145. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999;340(12):937-944.
146. Smith BJ, Hender K, Frith P, Crockett AJ, Cheok F, Spedding S. Systematic assessment of
clinical practice guidelines for the management of chronic obstructive pulmonary disease. Respir
Med 2003;97(1):37-45.
147. Soroksky A, Stav D, Shpirer I. A pilot prospective, randomized, placebo-controlled trial of
bilevel positive airway pressure in acute asthmatic attack. Chest 2003;123(4):1018-1025.
148. Steiner MC, Barton RL, Singh SJ, Morgan MD. Nutritional enhancement of exercise
performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax
2003;58(9):745-751.
149. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S,
Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease. Eur Respir J 2003;21(1):74-81.
150. Taube C, Kanniess F, Gronke L, Richter K, Mucke M, Paasch K, Eichler G, Jorres RA,
Magnussen H. Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in
patients with COPD or asthma. Respir Med 2003;97(5):568-577.
151. Trayner E, Jr., Celli BR. Postoperative pulmonary complications. Med Clin North Am
2001;85(5):1129-1139.
152. Trupin L, Earnest G, San Pedro M, Balmes JR, Eisner MD, Yelin E, Katz PP, Blanc PD. The
occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22(3):462-469.
153. van Beurden WJ, Harff GA, Dekhuijzen PN, van der Poel-Smet SM, Smeenk FW. Effects of
inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable
COPD patients. Respiration 2003;70(3):242-248.
154. van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP. Smoking cessation
for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003(2):CD002999.
155. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, Germann P,
Block LH. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of
the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax
2003;58(4):289-293.
156. Wagenaar M, Vos P, Heijdra Y, Teppema L, Folgering H. Comparison of acetazolamide and
medroxyprogesterone as respiratory stimulants in hypercapnic patients with COPD. Chest
2003;123(5):1450-1459.
157. Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Specific expiratory muscle
training in COPD. Chest 2003;124(2):468-473.
158. Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Comparison of specific
expiratory, inspiratory, and combined muscle training programs in COPD. Chest
2003;124(4):1357-1364.
159. Weisman IM. Cardiopulmonary exercise testing in the preoperative assessment for lung
resection surgery. Semin Thorac Cardiovasc Surg 2001;13(2):116-125.
160. Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM, Jr., Rodebaugh R,
Weinhous MS, Le QT. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I
trial. Ann Thorac Surg 2003;75(4):1097-1101.
161. Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days
compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in
the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med
2003;97(3):242-249.
162. Wise RA, Kanner RE, Lindgren P, Connett JE, Altose MD, Enright PL, Tashkin DP. The effect
of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung
Health Study. Chest 2003;124(2):449-458.
163. Witek TJ, Jr., Mahler DA. Minimal important difference of the transition dyspnoea index in a
multinational clinical trial. Eur Respir J 2003;21(2):267-272.
164. Witek TJ, Jr., Mahler DA. Meaningful effect size and patterns of response of the transition
dyspnea index. J Clin Epidemiol 2003;56(3):248-255.
165. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S.
Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease
patients. J Med Assoc Thai 2003;86(6):497-508.
166. Yohannes AM, Connolly MJ. Early mobilization with walking aids following hospital admission
with acute exacerbation of chronic obstructive pulmonary disease. Clin Rehabil 2003;17(5):465471.
167. Young W, Rewa G, Goodman SG, Jaglal SB, Cash L, Lefkowitz C, Coyte PC. Evaluation of a
community-based inner-city disease management program for postmyocardial infarction patients:
a randomized controlled trial. Cmaj 2003;169(9):905-910.
168. Zanotti E, Felicetti G, Maini M, Fracchia C. Peripheral muscle strength training in bed-bound
patients with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest
2003;124(1):292-296.
169. Zuhlke IE, Kanniess F, Richter K, Nielsen-Gode D, Bohme S, Jorres RA, Magnussen H.
Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD.
Eur Respir J 2003;22(6):926-930.